Med-tech giant Stryker (SYK)
isn't going to lead the pack every quarter or every year, but it's hard
to argue with the long-term performance of this company. Better still,
the company has never been one to rest on its laurels, with management
always looking for ways to improve its existing businesses and branch out into adjacent markets.
Stryker
doesn't look especially cheap right now, but that's about as surprising
as Wednesday following Tuesday given the company's almost four-year run
of mid single-digit organic revenue growth, its solid free cash flow
generation, and the prospects to improve margins and drive better
results from areas like robotics, imaging, neurovascular, and spine. I'm
not an enthusiastic buyer at this price, but Stryker's quality gives it
a near-permanent spot on my watch list, as the shares do occasionally
sell off and come back down into a buyable price range.
Read the full article here:
With Stryker, One Of The Best Always Seems To Get Better
No comments:
Post a Comment